Exhibit 99.1
ALIMERA SCIENCES REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS
Significant Progress in Development of Lead Product Candidate Iluvien®;
IPO completed; NDA on Track for 2Q10
ATLANTA, June 3, 2010 — Alimera Sciences, Inc., (NASDAQ: ALIM), (“Alimera”), today announced financial results for the first quarter ended March 31, 2010 and provided an update on progress toward achieving its 2010 goals.
“We have made important progress recently, including announcing positive results from the two Phase 3 FAME™ trials of our lead product candidate, Iluvien, in patients with diabetic macular edema (DME),” said Dan Myers, President and Chief Executive Officer of Alimera. “We remain on track to file a New Drug Application with the U.S. Food & Drug Administration in the second quarter. This would be followed by registration filings in various European countries and Canada. If approved, we believe Iluvien will be the first drug indicated for the treatment of DME.”
“DME and other retinal diseases are not well treated with current therapies. With our estimates of more than 300,000 new cases of DME annually and data that show diabetic retinopathy causes 12,000 to 24,000 new cases of blindness each year in the United States alone, we believe the addressable market for Iluvien could reach $1 billion per year. We remain optimistic that Alimera can provide a treatment to stem the debilitating effects of DME,” said Mr. Myers.
The recently announced FAME™ clinical trial data for the use of Iluvien in the treatment of DME demonstrated safety and statistical significance for efficacy at the 24 month clinical readout using the Full Analysis Set. The trials demonstrated statistical significance for the primary efficacy endpoint, which was the difference in the percentage of patients whose best corrected visual acuity improved by 15 or more letters from baseline on the ETDRS eye chart at month 24 between the treatment and control groups.
Financial Highlights
Net income for the quarter ended March 31, 2010 was $0.2 million, or $0.12 per common share, compared with a net loss of $12.0 million, or $8.07 per common share, for the quarter ended March 31, 2009.
In the first quarter of 2010, the Company also recognized income of $4.0 million from discontinued operations for an option payment received from Bausch & Lomb to extend by two years the period during
which it may develop an allergy product acquired from Alimera in 2006. Additionally, included in Alimera’s results for the first quarter of 2010 is a gain of $3.3 million associated with the decrease in the fair value of the conversion feature of Alimera’s preferred stock, compared with an expense of $4.2 million recognized in the first quarter of 2009 in connection with an increase in the fair value of the preferred stock conversion feature. The changes in fair value are primarily attributable to changes in the estimated fair value of Alimera’s common stock.
Research and development expenses for the quarter ended March 31, 2010 totaled $3.1 million, compared to $4.5 million for the first quarter of 2009. General and administrative expenses were $0.9 million for the first quarter of 2010, compared to $0.8 million for the first quarter of 2009. Marketing expenses were $0.3 million for the first quarter of 2010, compared to $0.2 million for the first quarter of 2009.
As of March 31, 2010, Alimera had cash, cash equivalents and marketable securities of $14.2 million, compared to $4.9 million as of December 31, 2009.
On April 21, 2010, Alimera completed its initial public offering of 6.55 million shares of common stock, resulting in net proceeds to Alimera of approximately $68.4 million. The closing of the sale of these shares occurred on April 27, 2010 and, therefore, the proceeds from the sale and the impact of the offering on earnings per share are not included in Alimera’s first quarter 2010 financial results. On April 27, 2010 the Company used a portion of these proceeds to pay off a $15 million note payable to the licensor of the Iluvien technology, pSivida US, Inc. Following the offering, the Company had 31,051,053 shares of common stock outstanding.
Conference Call to be Held Today
Alimera will hold a conference call and live webcast today at 4:30 p.m. ET. To participate in the call, please dial (877) 369-6586, in the U.S. or (253) 237-1165, for international callers. To access the live webcast, please visit the Investor Relations section on the corporate website at www.alimerasciences.com.
A replay of the conference call will be available beginning June 3, 2010 at 7:30 p.m. ET and ending on July 3, 2010 by dialing (800) 642-1687 in the U.S. or (706) 645-9291 for international callers. The Conference ID Number is: 76977260. A replay of the webcast will also be available on the corporate website for 30 days.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, Iluvien, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera’s future results of operations and financial position, business strategy and plans and objectives of management for Alimera’s future operations. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “likely,” “will,” “would,” “could,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The events and circumstances reflected in Alimera’s forward-looking statements may not occur and actual results could differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include, but are not limited to, delay in or failure to obtain regulatory approval of Alimera’s product candidates, uncertainty as to Alimera’s ability to
commercialize, and market acceptance of, its product candidates, the extent of government regulations, uncertainty as to the relationship between the benefits of Alimera’s product candidates and the risks of their side-effect profiles, dependence on third-party manufacturers to manufacture Alimera’s product candidates in sufficient quantities and quality, uncertainty of clinical trial results, limited sales and marketing infrastructure, as well as other factors discussed in Alimera’s Securities and Exchange Commission filings, including Alimera’s final prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission in connection with its initial public offering.
All forward-looking statements contained in this press release are expressly qualified by the above paragraph in their entirety. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Balance Sheets
(in thousands)
| | | | | | | | | |
| | | March 31, | | | December 31, | |
| | | 2010 | | | 2009 | |
| | | (unaudited) | | | | | |
| CURRENT ASSETS: | | | | | | | | |
| Cash and cash equivalents | | $ | 14,178 | | | $ | 4,858 | |
| Prepaid expenses and other current assets | | | 751 | | | | 634 | |
| Deferred offering costs | | | 1,093 | | | | 815 | |
| | | | | | | |
| | | | | | | | | |
| Total current assets | | | 16,022 | | | | 6,307 | |
| | | | | | | |
| | | | | | | | | |
| PROPERTY AND EQUIPMENT | | | 229 | | | | 254 | |
| | | | | | | |
| | | | | | | | | |
| TOTAL ASSETS | | $ | 16,251 | | | $ | 6,561 | |
| | | | | | | |
| | | | | | | | | |
| CURRENT LIABILITIES: | | | | | | | | |
| Accounts payable | | $ | 1,940 | | | $ | 1,215 | |
| Accrued expenses | | | 2,258 | | | | 3,314 | |
| Accrued interest | | | 901 | | | | 543 | |
| Outsourced services payable | | | 1,440 | | | | 1,157 | |
| Note payable | | | 6,000 | | | | 4,500 | |
| Capital lease obligations | | | 5 | | | | 6 | |
| | | | | | | |
| | | | | | | | | |
| Total current liabilities | | | 12,544 | | | | 10,735 | |
| | | | | | | |
| | | | | | | | | |
| LONG-TERM LIABILITIES: | | | | | | | | |
| Note payable — less current portion | | | 9,000 | | | | 10,500 | |
| Fair value of preferred stock conversion feature | | | 36,907 | | | | 36,701 | |
| Other long-term liabilities | | | 524 | | | | 708 | |
| | | | | | | | | |
| PREFERRED STOCK: | | | | | | | | |
| Series A preferred stock | | | 37,026 | | | | 36,467 | |
| Series B preferred stock | | | 41,271 | | | | 40,617 | |
| Series C preferred stock | | | 34,092 | | | | 33,452 | |
| Series C-1 preferred stock | | | 11,382 | | | | 2,853 | |
| STOCKHOLDERS’ DEFICIT: | | | | | | | | |
| Common stock | | | 56 | | | | 54 | |
| Additional paid-in capital | | | 5,090 | | | | 4,836 | |
| Series C-1 preferred stock warrants | | | — | | | | 1,472 | |
| Common stock warrants | | | 57 | | | | 57 | |
| Accumulated deficit | | | (171,698 | ) | | | (171,891 | ) |
| | | | | | | |
| | | | | | | | | |
| Total stockholders’ deficit | | | (166,495 | ) | | | (165,472 | ) |
| | | | | | | |
| | | | | | | | | |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | | $ | 16,251 | | | $ | 6,561 | |
| | | | | | | |
Income Statement
(in thousands except share and per share data)
| | | | | | | | | |
| | | Three Months Ended March 31, | |
| | | 2010 | | | 2009 | |
| RESEARCH AND DEVELOPMENT EXPENSES | | $ | 3,065 | | | $ | 4,528 | |
| GENERAL AND ADMINISTRATIVE EXPENSES | | | 904 | | | | 771 | |
| MARKETING EXPENSES | | | 247 | | | | 191 | |
| | | | | | | |
| | | | | | | | | |
| OPERATING EXPENSES | | | 4,216 | | | | 5,490 | |
| INTEREST INCOME | | | 2 | | | | 23 | |
| INTEREST EXPENSE | | | (474 | ) | | | (474 | ) |
(INCREASE) DECREASE IN FAIR VALUE OF PREFERRED
STOCK CONVERSION FEATURE | | | 3,265 | | | | (4,237 | ) |
| | | | | | | |
| | | | | | | | | |
| LOSS FROM CONTINUING OPERATIONS | | | (1,423 | ) | | | (10,178 | ) |
| INCOME FROM DISCONTINUED OPERATIONS | | | 4,000 | | | | — | |
| | | | | | | |
| | | | | | | | | |
| NET INCOME ( LOSS) | | | 2,577 | | | | (10,178 | ) |
| PREFERRED STOCK ACCRETION | | | (359 | ) | | | (107 | ) |
| PREFERRED STOCK DIVIDENDS | | | (2,025 | ) | | | (1,747 | ) |
| | | | | | | |
| | | | | | | | | |
| NET INCOME (LOSS) APPLICABLE TO COMMON SHAREHOLDERS | | $ | 193 | | | $ | (12,032 | ) |
| | | | | | | |
| | | | | | | | | |
NET INCOME (LOSS) PER SHARE APPLICABLE TO
COMMON SHAREHOLDERS — Basic and diluted | | $ | 0.12 | | | $ | (8.07 | ) |
| | | | | | | |
| | | | | | | | | |
WEIGHTED — AVERAGE SHARES OUTSTANDING — Basic
and diluted | | | 1,619,011 | | | | 1,490,138 | |
| | | | | | | |
